通化金马(000766) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥151,452,899.87, a decrease of 63.01% compared to ¥409,397,546.32 in the same period last year[3] - The net profit attributable to shareholders was -¥44,419,586.26, representing a decline of 187.21% from ¥50,931,985.61 in the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥56,565,311.12, a decrease of 239.04% compared to ¥40,683,222.82 last year[3] - Operating revenue decreased by 63.01% due to the impact of the pandemic on sales[9] - The net profit for Q1 2020 was a loss of ¥44,659,282.41, compared to a profit of ¥50,644,468.36 in Q1 2019, indicating a shift in financial performance[26] - The net profit for the first quarter of 2020 was CNY 14,241,505.68, a significant decrease compared to CNY 87,921,660.43 in the same period last year[30] - Basic and diluted earnings per share for Q1 2020 were both -¥0.0460, compared to ¥0.0527 in the previous year[28] - The total comprehensive income for the first quarter was CNY 14,241,505.68, compared to CNY 87,921,660.43 in the previous year[31] Cash Flow - The net cash flow from operating activities improved to ¥26,046,278.34, a 140.84% increase from -¥63,776,462.86 in the same period last year[3] - Net cash flow from operating activities increased by 140.84% due to a reduction in payments for goods and prepayments compared to the same period last year[9] - The net cash flow from investing activities decreased by 841.59% due to the acquisition of a 15% stake in Longmei Hospital[9] - The net cash flow from financing activities increased by 245,547.21% due to an increase in loans compared to the same period last year[9] - The cash outflow from investing activities was CNY 494,586,818.61, compared to CNY 337,440,947.98 in the same period last year[33] - The net cash flow from investing activities was -489,480,070.21 CNY, indicating significant cash outflows related to investments[36] - The net cash flow from financing activities was 182,702,800.25 CNY, primarily driven by cash received from borrowings of 198,750,000.00 CNY[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,658,224,363.33, an increase of 20.44% from ¥4,698,048,449.36 at the end of the previous year[3] - The total liabilities reached CNY 3,036,899,387.00, up from CNY 2,032,064,190.62, which is an increase of approximately 49.4%[20] - The company's equity attributable to shareholders decreased to CNY 2,586,511,331.23 from CNY 2,630,930,917.49, a decline of about 1.7%[21] - The total liabilities as of the end of Q1 2020 were ¥2,138,654,372.63, compared to ¥1,153,714,757.53 at the end of the previous year, indicating increased leverage[24] - The total current liabilities amounted to CNY 911,454,123.66, slightly up from CNY 905,034,652.99, indicating a marginal increase of about 0.5%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 46,599[5] - The largest shareholder, Beijing Jinshang Alliance Investment Management Co., Ltd., held 24.98% of the shares[5] - The company did not engage in any repurchase transactions during the reporting period[6] Investments and Acquisitions - The company plans to acquire 85% stakes in Jixi Jikuang Hospital and Shuangyashan Shuangkuang Hospital for an initial consideration of 153 million yuan[10] - Prepayments surged by 1489.89% due to the acquisition of a 15% stake in Longmei Hospital and prepayments for the acquisition of funds from Heilongjiang Property Exchange[9] - Goodwill increased by 92.23% as a result of the acquisition of Harbin Shengtai Pharmaceutical's stake in Harbin Cezhan Pharmaceutical[9] Research and Development - Research and development expenses rose by 128.63% due to increased investment in R&D projects[9] - Research and development expenses increased to ¥8,425,926.98 in Q1 2020, up from ¥3,685,405.11 in the same period last year, highlighting a focus on innovation[25] Government Support - The company received government subsidies amounting to ¥14,840,456.33 during the reporting period[4] Financial Structure - The company's cash and cash equivalents increased to CNY 638,244,758.35 from CNY 150,219,230.03, reflecting a growth of approximately 325.5%[22] - The company incurred a credit impairment loss of CNY -6,168,475.17 during the quarter[30] - The company has a long-term debt of 983,211,736.24 CNY, indicating a significant leverage position[40]